These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 21920388

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.
    Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H.
    Antiviral Res; 2010 Mar; 85(3):512-9. PubMed ID: 20034521
    [Abstract] [Full Text] [Related]

  • 3. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S, Sebastiani G, Rossi C, Velo E, Erne EM, Vario A, Tempesta D, Romualdi C, Campagnolo D, Alberti A.
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [Abstract] [Full Text] [Related]

  • 6. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
    Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spanò A, Cappiello G, Perno CF.
    J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent.
    Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P.
    Intervirology; 2012 Mar; 55(1):36-44. PubMed ID: 21311172
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
    Luo Q, Zhong Y, Yang Y, Xiong Q, Hu Z, Lu W, Huang P, Zhang N.
    J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
    Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, Ren X, Zhong Y, Zhao J, Xu D.
    J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B.
    Sayan M, Akhan SC, Meric M.
    J Viral Hepat; 2010 Jan; 17(1):23-7. PubMed ID: 19566788
    [Abstract] [Full Text] [Related]

  • 16. Characterization of hepatitis virus B isolated from a multi-drug refractory patient.
    Wei C, Chong YT, Wen JZ, Li YW, Li G.
    Virus Res; 2011 Jan; 155(1):254-8. PubMed ID: 20970466
    [Abstract] [Full Text] [Related]

  • 17. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, Trautwein C, Tacke F.
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
    Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F.
    Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.